News about "GSK plc "

GSK to Acquire Chimagen's Trispecific T-Cell Engager for Multiple Myeloma

GSK agrees to acquire global rights to Chimagen Biosciences’ investigational trispecific T-cell engager for multiple myeloma in a deal valued at up to USD 750 million.

GSK Plc | 16/09/2026 | By News Bureau

GSK's Shingrix Prefilled Syringe Approves in Japan

GSK’s Shingrix prefilled syringe receives approval in Japan for the prevention of shingles, offering a ready-to-use alternative to the existing two-vial presentation.

GSK Plc | 11/09/2026 | By News Bureau

Hutchmed Grants GSK Worldwide Rights to KRAS-EGFR Cancer Drug Candidate HMPL-A830

Hutchmed and GSK partner to advance HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy conjugate for solid tumours.

GSK Plc | 04/09/2026 | By News Bureau |  101

GSK's Jemperli Receives FDA Priority Review for dMMR/MSI-H Locally Advanced Rectal Cancer

GSK’s Jemperli has received FDA priority review for previously untreated dMMR/MSI-H locally advanced rectal cancer, following positive phase 2 AZUR-1 results.

GSK Plc | 26/08/2026 | By News Bureau |  116

GSK Receives Japan's First Approval for Bepirovirsen as Functional Cure for Chronic Hepatitis B

Japan’s MHLW approves Hibsago for eligible adults with chronic hepatitis B, following Phase 3 data showing a 19 percent functional cure rate after six months of treatment.

GSK Plc | 25/08/2026 | By News Bureau |  216

Hansoh Pharma Reports Positive Phase 3 Results for Ris-Rez in China

Hansoh Pharma reported positive phase 3 results for Ris-Rez in China, while GSK advances development across lung cancer, prostate cancer and other solid tumors.

GSK Plc | 31/07/2026 | By News Bureau

GSK to Establish New Global R&D Centre in Cambridge to Accelerate Drug Discovery

GSK will establish a 300,000 sq. ft. global R&D centre at the Cambridge Biomedical Campus, bringing together more than 1,000 scientists to accelerate medicines discovery through closer collaboration with leading academic, clinical and biotechnology partners.

GSK Plc | 30/07/2026 | By News Bureau

GSK's Efimosfermin Secures FDA Breakthrough and EMA PRIME Status for MASH Treatment

The dual regulatory designations from US FDA and European Medicines Agency fast-track development of GSK’s investigational liver therapy for metabolic dysfunction-associated steatohepatitis.

GSK Plc | 29/04/2026 | By News Bureau |  258

GSK plc Secures China Approval for Blenrep Combination Therapy in Multiple Myelom

National Medical Products Administration approves Blenrep with bortezomib and dexamethasone for relapsed or refractory patients, backed by strong phase III trial outcomes.

GSK Plc | 21/04/2026 | By News Bureau |  157

GSK plc Secures Japan Orphan Drug Status for Ris-Rez in Small-Cell Lung Cancer

Japan’s health ministry grants orphan drug designation to GSK’s investigational ADC Ris-Rez for SCLC, supported by early clinical data showing durable responses in advanced-stage patients.

GSK Plc | 24/03/2026 | By News Bureau |  224